Eurofins Technologies Serological Assays Demonstrate Ability to Identify Neutralizing Antibodies
Eurofins Technologies Serological Assays Demonstrate Ability to Identify Neutralizing Antibodies
Eurofins Technologies (Paris:ERF) recently launched multiple serological assay solutions to detect antibodies targeted against the Nucleocapsid protein of the novel Coronavirus. Antibody tests can be used to identify individuals who have been previously exposed to the virus and in some cases those who have an active infection. However, simple presence of antibodies in an individual does not guarantee immunity to further infections since only a fraction of antibodies provide the ability to neutralize the virus upon a second contact. Currently, elaborate tests requiring high biological safety measures are required to identify these neutralizing antibodies.
歐洲鰭科技（巴黎：ERF）最近推出了多種血清學分析解決方案，以檢測針對新型冠狀病毒核囊蛋白的抗體。抗體測試可用於識別以前暴露於該病毒的個人以及在某些情況下，那些患有活躍感染的人。但是，單獨存在抗體並不能保證對進一步感染的免疫力，因為只有一小部分抗體提供 能力 在第二次接觸時中和病毒。目前，需要進行高生物安全措施的詳細測試來確定這些中和抗體。
Now, a study performed by Eurofins Ingenasa has demonstrated a direct correlation between Eurofins Technologies antibody detection assays and seroneutralization capability of the antibodies detected without the need to perform time-consuming and complex tests including high biological hazard. For this study, 55 blood samples were tested on the INgezim total antibody ELISA and a subset of samples on the VIROTECH SARS-CoV-2 IgG/IgM/IgA ELISA and the results compared to a virus seroneutralization test. This test takes multiple days and includes infection of cell culture with SARS-CoV-2 to detect those antibodies that protect human cells from entering of the virus. In 100% of tested blood samples, the result of the ELISA tests was identical to the seroneutralization assay even though the same result was obtained in less than 2 hours.
現在, 由 Eurofins Inenasa 進行的一項研究已經證明 Eurofins 技術抗體檢測檢測和檢測到的抗體的血清化能力之間的直接相關性，而無需執行耗時和複雜的測試，包括高生物危害.對於這項研究，在 IngEZIM 總抗體 ELISA 上進行了 55 個血液樣本 test，並在病毒新型 SARS-CoV-2 IGM/IGM/IGA ELISA 上進行了一部分樣本測試，結果與病毒血清化測試相比。該 test 需要數天的時間，包括使用 SARS-CoV-2 感染細胞培養，以檢測那些保護人類細胞免受病毒進入的抗體。在 100％ 的測試血液樣本中，ELISA 測試的結果與血清化分析相同，即使在不到 2 小時內獲得相同的結果。
Similarly, a study was performed by the NYU Grossman School of Medicine and NYU Langone Health comparing the results of another Eurofins Technologies ELISA using the same technology (GSD SARS-CoV-2 ELISA) to a seroneutralization assay. The study shows a strong correlation between the IgG isotype specific ELISA and the ability of the antibodies in the blood samples to neutralize SARS-CoV-2.
同樣，紐約大學格羅斯曼醫學院和紐約大學朗貢健康學院進行了一項研究，比較了使用相同技術（GSD SARS-CoV-2 ELISA）的另一種歐洲鰭技術 ELISA 的結果與血清化分析。該研究表明，IgG 同型特異性 ELISA 與血液樣本中抗體中和 SARS-CoV-2 的能力之間具有很強的相關性。
For more information, please visit the Eurofins Technologies webpage
欲了解更多信息，請訪問歐匯科技網頁
Notes for the editor:
編輯注意事項：
About Eurofins – the global leader in bio-analysis
關於歐洲鰭 — 生物分析領域的全球領導者
Eurofins is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in esoteric and molecular clinical diagnostic testing.
Eurofins 是食品，環境，醫藥和化妝品產品測試以及農業科學 CRO 服務的全球領導者。它也是基因組學、發現藥理學、取證、先進材料科學以及深奧和分子臨床診斷測試的測試和實驗室服務的全球市場領導者之一。
With over48,000 staffacross a network of more than800 laboratoriesin over50 countries, Eurofins’ companies offer a portfolio of over200,000 analytical methods.
隨著超過四萬八千名員工跨越一個以上的網絡800 個實驗室在結束50 個國家，歐洲金融公司提供的投資組合超過20 萬種分析方法
Eurofins Shares are listed on Euronext Paris Stock Exchange.
歐洲股票在泛歐交易所巴黎證券交易所上市。
譯文內容由第三人軟體翻譯。